Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2023-07-26 Proxy Solicitation & In…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) issued by PharmAbcine. It contains the meeting agenda, details on director and auditor nominations, and proposed amendments to the articles of incorporation. This type of document is sent to shareholders to provide information and request votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2023-07-26 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to provide shareholders with information regarding upcoming shareholder meetings (in this case, an Extraordinary General Meeting) and to solicit their votes. This document contains details about the meeting agenda, director/auditor candidates, and voting procedures. This falls under the 'Proxy Solicitation & Information Statement' category.
2023-07-26 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for the company PharmAbcine. It details the issuance of new shares, the purpose of the capital increase, the third-party allocation details, and includes a correction notice (정정신고) for the payment date. This falls under the category of announcements regarding new share issues or capital changes.
2023-07-26 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a change in the largest shareholder of the company 'PharmAbcine'. It details the transfer of shares, the identity of the new major shareholder (Ucon Partners), the purpose of the acquisition (management participation), and financial details of the acquiring entity. This type of disclosure is a standard regulatory announcement regarding corporate control and ownership structure, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to business combinations) or Director's Dealing (which refers to individual insider trades).
2023-07-26 Korean
신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (PharmAbcine) detailing the acquisition of its own bonds (specifically, bonds with warrants) before maturity. This falls under capital structure changes and financing activities. Since it specifically details the repurchase/acquisition of debt instruments, it aligns best with the 'Capital/Financing Update' category.
2023-07-24 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Pharmabcine, specifically detailing a 'Capital Increase' (유상증자결정) and a subsequent amendment (정정신고) to the payment date, share issuance date, and listing date. This document falls under the category of announcements regarding new share issues and capital structure changes, which is classified as 'Share Issue/Capital Change'.
2023-07-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.